Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease

Journal of the American College of Cardiology

Volumn 31, Issue 4, 1998, Pages 827-832

  Maass, Matthias ^a   Bartels, Claus ^a   Engel, Peter M ^a   Mamat, Uwe ^b   Sievers, Hans Hinrich ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ATHEROGENESIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PATHOGENESIS; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DNA, BACTERIAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 0032521232     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00016-3     Document Type: Article

References (35)

1. 1. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986;315:161-8.
2. 2. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995;8:451-61.
3. 3. Dalhoff K, Maass M. Chlamydia pneumoniae pneumonia in hospitalized patients: clinical characteristics and diagnostic value of PCR detection in BAL. Chest 1996;110:351-6.
4. 4. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
5. 5. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992;116:273-8.
6. 6. Thom DH, Wang SP, Grayston JT. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991;11:547-51.
7. 7. Maass M, Gieffers J. Prominent serological response to Chlamydia pneumoniae in cardiovascular disease. Immunol Infect Dis 1996;6:65-70.
8. 8. Mendall MA, Carrington D, Strachan D, et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995;30:121-8.
9. 9. Maass M, Gieffers J. Cardiovascular disease risk from prior Chlamydia pneumoniae infection can be related to certain antigens recognized in the immunoblot profile. J Infect 1997;35:171-6.
10. 10. Libby P. Atheroma: more than mush. Lancet 1996;348 Suppl I:S4-7.
11. 11. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992;82:158-61.
12. 12. Weiss SM, Roblin PM, Gaydos CA, et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996;173:957-62.
13. 13. Campbell LA, O'Brien ER, Cappuccio AL, et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995;172:585-8.
14. 14. Maass M, Harig U. Evaluation of culture conditions used for isolation of Chlamydia pneumoniae. Am J Clin Pathol 1995;103:141-8.
15. 15. Maass M, Dalhoff K. Transport and storage conditions for cultural recovery of Chlamydia pneumoniae. J Clin Microbiol 1995;33:1793-6.
16. 16. Maass M, Krause E, Engel PM, Krüger S. Endovascular presence of Chlamydia pneumoniae in patients with hemodynamically effective carotid artery stenosis. Angiology 1997;48:699-706.
17. 17. Maass M, Dalhoff K. Comparison of sample preparation methods for detection of Chlamydia pneumoniae in bronchoalveolar lavage fluid by PCR. J Clin Microbiol 1994;32:2616-9.
18. 18. Campbell LA. PCR detection of Chlamydia pneumoniae. In: Persing DH, Smith TF, Tenover FC, White TJ, editors. Diagnostic Molecular Microbiology: Principles and Applications. Washington, DC: American Society for Microbiology, 1993:247-52.
19. 19. Dragon EA, Spadoro JP, Madej R. Quality control of polymerase chain reaction. In: Persing DH, Smith TF, Tenover FC, White TJ, editors. Diagnostic Molecular Microbiology: Principles and Applications. Washington (DC): American Society for Microbiology, 1993:160-8.
20. 20. Kubota Y. A new primer pair for detection of Chlamydia pneumoniae by polymerase chain reaction. Microbiol Immunol 1996;40:27-32.
21. 21. Perez Melgosa M, Kuo CC, Campbell LA. Isolation and characterization of a gene encoding a Chlamydia pneumoniae 76-kilodalton protein containing a species-specific epitope. Infect Immun 1994;62:880-6.
22. 22. Gaydos CA, Quinn TC, Eiden JJ. Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene. J Clin Microbiol 1992;30:796-800.
23. 23. Kornak JM, Kuo CC, Campbell LA. Sequence analysis of the gene encoding the Chlamydia pneumoniae DnaK protein homolog. Infect Immun 1991;59: 721-5.
24. 24. Essig A, Zucs P, Susa M, et al. Diagnosis of ornithosis by cell-culture and polymerase chain reaction in a patient with chronic pneumonia. Clin Infect Dis 1995;21:1495-7.
25. 25. Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996;27:1555-61.
26. 26. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993;167:841-9.
27. 27. Wissler RW. Significance of Chlamydia pneumoniae (TWAR) in atherosclerotic lesions [editorial]. Circulation 1995;92:3376.
28. 28. Ramirez JA, for the Chlamydia pneumoniae/Atherosclerosis Study Group. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary arteriosclerosis. Ann Intern Med 1996;125:979-82.
29. 29. Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor-Robinson D. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 1996;49:102-6.
30. 30. Kuo CC, Jackson LA, Lee A, Grayston JT. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1996;40:2669-70.
31. 31. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B, for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404-7.
32. 32. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96:404-7.
33. 33. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995;57:791-804.
34. 34. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997;175: 883-90.
35. 35. Falkow S. Molecular Koch's postulates applied to microbial pathogenesis. Rev Infect Dis 1988;10 Suppl S2:S274-6.